Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs FTAI Aviation Ltd — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while FTAI Aviation Ltd trades at $212.01 (market cap $21.17B). The key difference: FTAI Aviation Ltd is far larger — about 2.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and FTAI Aviation Ltd pays a 0.73% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | FTAI | |
|---|---|---|
Market Cap | $8.04B | $21.17B |
Sector | Health | Industrials |
52-Week High | $339.75 | $310.04 |
52-Week Low | $241.71 | $109.92 |
Enterprise Value | $7.85B | $24.21B |
Dividend Yield | — | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
FTAI Aviation trades at $209.88, down 7.68% today, amid a bearish technical signal. The stock has missed earnings estimates for three consecutive quarters, though revenue and net income remain robust. Recent news highlights strategic collaborations and growth in data center power solutions. Analyst consensus is unanimously bullish with 18 buy ratings.
The outlook is supported by strong fundamentals and growth initiatives, but risks include earnings misses and high valuation multiples. The stock's near-term performance hinges on Q2 2026 results and execution of new business segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
